Tafamidis Meglumine Patent Expiration
Tafamidis Meglumine is Used for treating the cardiomyopathy associated with transthyretin-mediated amyloidosis. It was first introduced by Foldrx Pharmaceuticals Llc A Wholly Owned Sub Of Pfizer Inc
Tafamidis Meglumine Patents
Given below is the list of patents protecting Tafamidis Meglumine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vyndaqel | US7214695 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | Dec 19, 2025 | Foldrx Pharms |
| Vyndaqel | US7214696 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | Dec 19, 2025 | Foldrx Pharms |
| Vyndaqel | US8168663 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof |
Dec 19, 2023
(Expired) | Foldrx Pharms |
| Vyndaqel | US8653119 | Methods for treating transthyretin amyloid diseases |
Dec 19, 2023
(Expired) | Foldrx Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tafamidis Meglumine's patents.
Latest Legal Activities on Tafamidis Meglumine's Patents
Given below is the list recent legal activities going on the following patents of Tafamidis Meglumine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 29 Apr, 2024 | US7214696 |
| Second letter to regulating agency to determine regulatory review period | 29 Apr, 2024 | US7214695 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 Feb, 2024 | US7214695 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 Feb, 2024 | US7214696 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Oct, 2023 | US8168663 |
| Interim Patent Term Extension Granted Critical | 13 Oct, 2023 | US7214695 |
| Interim Patent Term Extension Granted Critical | 13 Oct, 2023 | US7214696 |
| Email Notification Critical | 23 Aug, 2023 | US8168663 |
| Change in Power of Attorney (May Include Associate POA) Critical | 23 Aug, 2023 | US8168663 |
| Change in Power of Attorney (May Include Associate POA) Critical | 22 Aug, 2023 | US8653119 |
Tafamidis Meglumine's Family Patents
